HGH vs TRT: Which Therapy Is Right for You?

Two of the most commonly discussed hormonal therapies for men — testosterone replacement therapy (TRT) and human growth hormone (HGH) therapy — are frequently confused, compared, and conflated. Men researching one often encounter the other. Forums mix them together. Marketing blurs the lines between them. And yet they address fundamentally different hormonal systems, different deficiencies, and produce different clinical outcomes.

The question “which one is right for me?” is the correct question to ask. But the answer depends entirely on what’s actually deficient — which can only be established through proper laboratory evaluation. This article breaks down how the two therapies differ, where they overlap, and the clinical framework for understanding which, if either, might be relevant to your situation.

The Fundamental Difference: Two Separate Hormonal Axes

TRT and HGH therapy operate on completely different hormonal systems. This isn’t a subtle distinction — it’s foundational to understanding why one might be appropriate for a given person and the other might not.

Testosterone replacement therapy addresses deficiency in the hypothalamic-pituitary-gonadal (HPG) axis. The testes produce testosterone under the direction of LH and FSH from the pituitary, which in turn respond to GnRH from the hypothalamus. When this axis fails — either at the testicular level (primary hypogonadism) or at the pituitary/hypothalamic level (secondary hypogonadism) — testosterone falls and symptoms develop. TRT corrects this by delivering testosterone exogenously.

HGH therapy addresses deficiency in the hypothalamic-pituitary-somatotropic axis. Growth hormone is produced by the anterior pituitary in response to GHRH from the hypothalamus. It acts partly directly and partly through IGF-1, which the liver produces in response to GH. When this axis fails — typically due to pituitary or hypothalamic disease, radiation, trauma, or surgery — GH falls and adult growth hormone deficiency (AGHD) develops. HGH therapy corrects this by delivering recombinant growth hormone.

The two axes are parallel but distinct. A man can have low testosterone with normal GH. He can have confirmed AGHD with normal testosterone. He can have both deficiencies simultaneously — which is more common than many people realize, particularly in men with pituitary pathology. And he can have neither, with symptoms driven by other causes entirely.

For a comprehensive overview of TRT, the complete guide to testosterone replacement therapy covers the full evaluation and treatment process. For HGH therapy specifically, the HGH therapy overview covers who qualifies and what treatment involves.

What Each Hormone Does: The Practical Effects

Understanding what each hormone does in the adult male body helps clarify why their deficiencies produce different symptom patterns — and why the right therapy depends on which system is actually impaired.

Symptom Overlap: Why This Is Confusing

The clinical picture of testosterone deficiency and growth hormone deficiency overlap substantially — which is the primary reason men (and sometimes clinicians) confuse them. Fatigue, reduced muscle mass, increased body fat, low mood, and reduced exercise capacity appear in both conditions. Several symptoms do, however, differ in pattern and prominence.

Table 1 — Symptom prominence comparison. “Prominent” = consistently documented in peer-reviewed literature on confirmed deficiency. These are clinical patterns for orientation only — differential diagnosis requires laboratory testing. For more detail on low-T symptoms, see the overview of hormonal symptoms in men over 50. For GH-specific signs, the 7 signs of low growth hormone covers the full clinical picture.

How Each Is Diagnosed: Different Tests, Different Criteria

Because TRT and HGH therapy address different hormonal axes, their diagnostic processes are distinct — and cannot substitute for each other.

Diagnosing testosterone deficiency

Testosterone deficiency requires two separate morning testosterone measurements (total testosterone) below the reference range, combined with clinical symptoms. Current Endocrine Society and AUA guidelines require both biochemical confirmation and symptomatic presentation before treatment is initiated. Additional markers — free testosterone, LH, FSH, prolactin, estradiol — help characterize the type and cause of deficiency.

A single testosterone reading is insufficient. Morning timing is essential — testosterone peaks between 7–10 AM and can read 20–30% lower in the afternoon. The full diagnostic workup for testosterone is covered in the step-by-step guide to starting TRT and in more detail in the first consultation guide.

Diagnosing growth hormone deficiency

AGHD diagnosis is more complex. A low IGF-1 level is the first-line screen — but it is not diagnostic on its own, as IGF-1 can be low due to malnutrition, hypothyroidism, liver disease, or other causes unrelated to GH axis function.

Confirmed AGHD requires a dynamic stimulation test — typically an insulin tolerance test (ITT) or glucagon stimulation test — that demonstrates an inadequate GH response below established clinical thresholds. This is an inpatient or monitored outpatient procedure and cannot be completed with a standard blood draw. Clinical context (history of pituitary disease, brain radiation, traumatic brain injury) is factored into the interpretation.

This is why AGHD is less commonly diagnosed than testosterone deficiency — the diagnostic bar is higher, as it should be for a condition requiring a more complex treatment. The full diagnostic pathway is covered in the HGH therapy overview.

How Each Is Treated: Mechanisms and Protocols

The treatment approaches are structurally similar — both typically involve subcutaneous injection — but differ in mechanism, dosing rationale, and what’s being replaced or stimulated.

TRT protocols

TRT delivers testosterone directly — bypassing the body’s own production system. The most common and cost-effective delivery method is weekly or twice-weekly subcutaneous injection of testosterone cypionate or enanthate. Other options include topical gels, transdermal patches, pellet implants, and oral tablets. Each has different pharmacokinetics, cost, and practical tradeoffs.

A detailed comparison of TRT delivery options is in the complete TRT guide, and the pellets vs. injections decision specifically is covered in the pellets vs. injections comparison. For cost information, the TRT cost breakdown covers pricing by method and care model.

HGH therapy protocols

HGH therapy delivers recombinant human growth hormone via daily subcutaneous injection, typically in the evening to align with the body’s natural GH secretion during sleep. Starting doses are conservative — typically 0.1–0.3 mg/day — and are titrated based on IGF-1 response and clinical symptoms over 4–6 months.

Unlike TRT, HGH therapy cannot be self-initiated based on a simple prescription — the indication requires confirmed deficiency through stimulation testing, which requires specialist involvement. It is also significantly more expensive than TRT, and insurance coverage for AGHD requires documented pituitary pathology in most plans.

Peptide alternatives to direct HGH

For men without confirmed pituitary disease but with sub-optimal GH output, growth hormone secretagogue peptides — Sermorelin, CJC-1295, Ipamorelin — stimulate the pituitary to produce more of its own GH rather than replacing it directly. This approach preserves the natural GH axis and may be more appropriate for men with functional pituitaries. The comparison of the main peptide options is covered in the BPC-157, Sermorelin, CJC-1295 guide, and the broader peptide therapy context is in the peptide therapy overview.

Head-to-Head: TRT vs HGH Therapy

Table 2 — TRT vs. HGH therapy comparison. Cost ranges are general U.S. market estimates as of 2026. The right therapy depends on which hormonal deficiency is confirmed through laboratory evaluation — not on symptoms alone.

Can You Do Both? When Concurrent Therapy Makes Sense

Men with pituitary disease or hypothalamic pathology frequently have both testosterone deficiency and GH deficiency simultaneously. The pituitary controls both the HPG axis (through LH and FSH) and the somatotropic axis (through GH release). When pituitary function is impaired — by tumor, surgery, radiation, or trauma — multiple hormonal systems often fail together.

In these cases, treating only one deficiency produces incomplete results. A man with confirmed AGHD and secondary hypogonadism who receives only TRT may see improvements in libido and muscle mass without the visceral fat reduction, exercise capacity improvement, and bone density recovery that GH replacement would provide. Concurrent therapy, when both deficiencies are confirmed, is supported by clinical guidelines and is managed with the monitoring requirements of both treatments.

The interaction between testosterone and growth hormone is synergistic in several areas — both support lean mass, both affect energy and mood, and their combined deficiency produces a more severe clinical picture than either alone. This is one reason that men with confirmed deficiency in both axes tend to show the most significant improvements when both are treated.

The connection to body composition and weight — a common concern for men with either or both deficiencies — is covered in the article on whether low testosterone causes weight gain.

The Decision Framework: Which Should You Investigate?

Frequently Asked Questions

Can I take HGH therapy to boost testosterone?

No. HGH and testosterone operate on separate hormonal axes and do not substitute for each other. HGH therapy raises IGF-1 and GH — it does not raise testosterone. Some research suggests GH may have modest positive effects on testicular function in men with both deficiencies, but this is not a reliable mechanism for testosterone restoration. If your primary concern is low testosterone, that requires evaluation and treatment of the HPG axis specifically.

Will TRT help if my primary problem is low growth hormone?

TRT will address testosterone deficiency symptoms — libido, mood, lean mass — but it will not correct GH deficiency symptoms. If your fatigue, visceral fat accumulation, and exercise intolerance persist despite adequate TRT, this may indicate a co-existing GH deficiency that warrants separate evaluation. Men who remain symptomatic on optimized TRT are sometimes found to have concurrent AGHD when IGF-1 is checked.

Which therapy is safer?

Both therapies, when appropriately prescribed for confirmed deficiency at physiological doses under physician supervision, have well-characterized safety profiles. TRT has a larger and longer evidence base, including the TRAVERSE trial (2023) which specifically evaluated cardiovascular safety in high-risk patients. HGH therapy for confirmed AGHD has decades of clinical use with documented safety at therapeutic doses. The risk profile changes substantially at supraphysiological doses — which is why “optimization” protocols that push levels above the normal physiological range are not the same as treating confirmed deficiency.

I’m already on TRT and still feel tired. Could I also need HGH?

Possibly. Persistent fatigue despite optimized TRT is one of the clinical patterns that warrants GH axis evaluation. The first step is confirming your TRT protocol is actually achieving therapeutic testosterone levels — trough levels below the lower-normal range produce inadequate symptom control regardless of the dose. If levels are adequate and fatigue persists, an IGF-1 check is a reasonable next step to screen for GH axis contribution. Sleep apnea and thyroid function are also worth evaluating, as both are common contributors to fatigue that persist on TRT.

Is HGH therapy the same as “anti-aging” GH treatments I see advertised?

No. FDA-approved HGH therapy (recombinant human growth hormone) is a prescription drug prescribed for specific diagnosed medical conditions — primarily confirmed AGHD. The “anti-aging” or “optimization” use of HGH in men without documented GHD is an off-label, non-FDA-approved application with a different risk-benefit profile. The evidence for HGH in aging adults without deficiency is limited, and the FDA explicitly does not approve its use for anti-aging purposes. This distinction matters both clinically and legally.

How do I know if I have low testosterone, low GH, or both?

Laboratory testing is the only reliable way to answer this question. For testosterone: total and free testosterone drawn on two separate mornings, with LH, FSH, and SHBG for context. For GH: morning IGF-1 as a first-line screen, followed by a stimulation test if IGF-1 is low. Both can be ordered at the same time with physician guidance, which is efficient for men with significant overlap in symptoms. For an overview of what the first evaluation looks like, the first TRT consultation guide covers the diagnostic process in detail.

What does HGH therapy cost compared to TRT?

HGH therapy is significantly more expensive than TRT. Recombinant HGH runs $3,000–$15,000+ annually depending on dose, brand, and insurance coverage. TRT with injectable testosterone, by comparison, costs $200–$800/year with insurance or $1,500–$4,000 without. Insurance coverage for HGH therapy requires documented AGHD with a clear pituitary cause — it is not covered for general wellness or age-related GH decline. For a full TRT cost breakdown by care model, see the TRT cost guide.

Are there alternatives to HGH injections?

Yes — for men without confirmed pituitary disease who want to support GH axis function, growth hormone secretagogue peptides (Sermorelin, CJC-1295, Ipamorelin) stimulate the pituitary to produce more of its own GH rather than replacing it directly. These require a functioning pituitary and have a lower evidence base than direct HGH therapy, but offer a less invasive and less costly approach for men with sub-optimal rather than clinically deficient GH output. This option is covered in detail in the peptide therapy comparison and the peptide therapy overview.

References

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229
2. Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(6):1587–1609. doi:10.1210/jc.2011-0179
3. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). N Engl J Med. 2023;389(2):107–117. doi:10.1056/NEJMoa2215025
4. Yuen KCJ, Biller BMK, Radovick S, et al. AACE/ACE Guidelines for Management of Growth Hormone Deficiency in Adults. Endocr Pract. 2019;25(11):1191–1232. doi:10.4158/GL-2019-0405
5. Hazem A, Elamin MB, Bancos I, et al. Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis. Eur J Endocrinol. 2012;166(1):13–20. doi:10.1530/EJE-11-0558
6. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611–624. doi:10.1056/NEJMoa1506119
7. U.S. National Library of Medicine. Hypogonadism and Growth Hormone Deficiency overview. MedlinePlus. medlineplus.gov/ency/article/000390.htm